Summary:
«Last week, the U.S. Food and Drug Administration presented the organization’s first Artificial Intelligence/Machine Learning (AI/ML)- Based Software as a Medical Device (SaMD) Action Plan. This plan portrays a multi-pronged way to deal with the Agency’s oversight of AI/ML-based medical software.
The Artificial Intelligence/Machine Learning (AI/ML)- Based Software as a Medical Device (SaMD) Action Plan is a response to stakeholder input on the FDA’s 2019 regulatory structure for AI and ML-based medical items.
FDA additionally will hold a public workshop on algorithm transparency and draw in its stakeholders and partners on other key activities, for example, assessing predisposition in algorithms. While the Action Plan proposes a guide for propelling a regulatory framework, an operational structure gives off an impression of being further down the road.»
Article written by Priya Dialani
19|01|2021
Source:
Analytics Insight